Literature DB >> 32032212

The Use of the Methadone/Metabolite Ratio (MMR) to Identify an Individual Metabolic Phenotype and Assess Risks of Poor Response and Adverse Effects: Towards Scientific Methadone Dosing.

John J McCarthy1, Joseph Graas, Martin H Leamon, Coburn Ward, Ernest J Vasti, Catherine Fassbender.   

Abstract

OBJECTIVES: Significant genetic variability of metabolism confounds reliable clinical use of methadone because physicians have no way of identifying individual patient metabolism. The methadone/metabolite ratio (MMR), the numerical ratio of serum methadone to its inactive metabolite ethylidine-dimethyl-diphenypyrrolidine (EDDP), represents the net expression of the genes controlling metabolism. The MMR has been adapted to four established pharmacogenetic metabolic categories: ultra-rapid (URM), extensive (EM, normal), intermediate (IM), and ultra-slow (USM).
METHODS: This study reports on the analysis of 1700 paired peak and trough serum samples for methadone and EDDP. The MMR data were stratified by metabolic category. The reliability of these categories and the relationship of the MMR to 2 other laboratory assessments, a peak/trough ratio (PTR) and a methadone half-life, was tested. Additionally, peak and trough serum levels were analyzed by MMR category.
RESULTS: Each category of MMR identified significantly different mean serum levels (peak and trough), peak/trough ratios, and half-lives. When serum levels were analyzed, evidence of subtherapeutic serum levels were found, predominantly in the URM and EM categories. Seventeen percent of peak serum levels were greater than 1000 ng (a level indicating potential toxicity) with a range up to 2384 ng, predominantly in the IM and USM categories.
CONCLUSIONS: The MMR measures an individual's phenotype for methadone metabolism. The data suggested underdosing in the URM category, as well as evidence of excessive dosing in IM and USM categories. The MMR provides a guide to safe and effective dosing, an alternative to the pharmacokinetically 'blind' dosing algorithms currently in use.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32032212     DOI: 10.1097/ADM.0000000000000620

Source DB:  PubMed          Journal:  J Addict Med        ISSN: 1932-0620            Impact factor:   3.702


  3 in total

1.  Potential for Precision Medicine in Methadone Treatment of Opioid Use Disorder.

Authors:  Andrew J Saxon
Journal:  J Addict Med       Date:  2020 Sep/Oct       Impact factor: 4.647

2.  Exploring the Potential of Implementing Managed Alcohol Programmes to Reduce Risk of COVID-19 Infection and Transmission, and Wider Harms, for People Experiencing Alcohol Dependency and Homelessness in Scotland.

Authors:  Tessa Parkes; Hannah Carver; Wendy Masterton; Hazel Booth; Lee Ball; Helen Murdoch; Danilo Falzon; Bernie M Pauly; Catriona Matheson
Journal:  Int J Environ Res Public Health       Date:  2021-11-28       Impact factor: 3.390

3.  Lower buprenorphine elimination rate constant is associated with lower opioid use.

Authors:  Hesham Farouk Elarabi; Amanda J Lee; Abdu Adem; Abuelgasim Elrasheed; John Marsden; Hamad Al Ghaferi
Journal:  Psychopharmacology (Berl)       Date:  2022-08-12       Impact factor: 4.415

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.